Every material Form 8-K CARLSMED, INC. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Carlsmed said CFO Leo Greenstein left the role effective September 25, 2026, and appointed Richard Heppenstall as CFO effective September 28, 2026. Greenstein's separation includes $500,000 in cash severance, accelerated vesting of some equity awards, and a $60,000 advisory fee through December 31, 2026. The company reaffirmed its full-year 2026 revenue guidance of $74 million to $78 million, so the leadership change did not come with a change to that outlook.
Greenstein's departure effective September 25, 2026; Heppenstall's appointment effective September 28, 2026.
Greenstein to receive $500,000 in cash payments, equal to 12 months of base salary, plus a $60,000 advisory fee.
Heppenstall's employment agreement sets a $500,000 base salary and a target bonus of 60% of base, with $1.4 million each in inducement stock options and RSUs.
Full-year 2026 revenue guidance of $74 million to $78 million was reaffirmed.
Carlsmed appointed Jeffrey Bertolini, previously its senior vice president of operational excellence, as chief operating officer effective September 8, 2026. His base salary rose to $475,000 and his target incentive rose to 60% of salary, and he received 50,000 stock options. The filing reports no financial results, so the change is a management appointment rather than a change in reported performance.
Jeffrey Bertolini, age 60, appointed chief operating officer by the board on September 4, 2026, effective September 8, 2026.
Base salary increased to $475,000 from $440,000; target annual incentive increased to 60% of base salary.
Granted 50,000 stock options on September 8, 2026.
Previously served as senior vice president, operational excellence, since March 2025, and joined the company in September 2024.
Carlsmed reported second quarter 2026 revenue of $18.9 million, up 57% from a year earlier, and raised its full-year 2026 revenue guidance to $74 million to $78 million from $72 million to $77 million. Its net loss widened to $10.5 million from $6.8 million, so higher sales came with larger losses for shareholders.
Q2 2026 revenue was $18.9 million, up from $12.1 million in Q2 2025.
Net loss was $10.5 million, compared with $6.8 million a year earlier; gross margin rose to 76.8% from 73.4%.
Full-year 2026 revenue guidance raised to $74 million to $78 million from $72 million to $77 million.
Cash, restricted cash, short-term investments and marketable securities totaled $89.3 million as of June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CARLSMED, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →